drugset / Trial / NCT05970705
Regorafenib Combined With TAS-102 Versus Regorafenib Monotherapy in Third or Later Line Therapy of mCRC
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the clinical benefit of regorafenib combined with TAS-102 compared with regorafenib monotherapy in patients with metastatic colorectal cancer who have failed at least two lines of treatment, to explore the rationality of this combination therapy strategy and to obtain relevant survival and safety data.
Timeline
- Start
- 2023-07-01
- Primary completion
- 2025-07-04
- Completion
- 2026-07-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Regorafenib | Small molecule | 80 mg | Oral |
| Subject | Regorafenib | Small molecule | 120 mg | Oral |
| Subject | Trifluridine/Tipiracil | Unknown | 35 mg/m2 | Oral |